[go: up one dir, main page]

NO933742L - Human, bone derived, insulin-like growth factor binding protein - Google Patents

Human, bone derived, insulin-like growth factor binding protein

Info

Publication number
NO933742L
NO933742L NO933742A NO933742A NO933742L NO 933742 L NO933742 L NO 933742L NO 933742 A NO933742 A NO 933742A NO 933742 A NO933742 A NO 933742A NO 933742 L NO933742 L NO 933742L
Authority
NO
Norway
Prior art keywords
binding protein
insulin
human
igf
bone
Prior art date
Application number
NO933742A
Other languages
Norwegian (no)
Inventor
Subburaman Mohan
David J Baylink
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of NO933742L publication Critical patent/NO933742L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Rensede og isolerte preparater av et bindingsprotein for insulin- lignende vekstfaktorer (IGF) I og II. Bindingsproteinet, kjent som humant, benavledet IGF-bindingsprotein (hBD- IGFBP), forsterker de proliferative effekter av IGF-II på benceller. Diag- nostiske analysebestemmelser for hBD- IGFBP, så vel som farmasøytiske prepar- ater og fremgangsmåter for behandling av bensykdommer, sårheling, hudrepara- sjon og midler for å modulere IGF- aktivitet i ben, er også beskrevet.Purified and isolated preparations of a binding protein for insulin-like growth factors (IGF) I and II. The binding protein, known as human, bone derived IGF binding protein (hBD-IGFBP), enhances the proliferative effects of IGF-II on bone cells. Diagnostic assays for hBD-IGFBP, as well as pharmaceutical preparations and methods for treating bone diseases, wound healing, skin repair, and agents for modulating bone IGF activity are also described.

NO933742A 1991-04-19 1993-10-18 Human, bone derived, insulin-like growth factor binding protein NO933742L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68835391A 1991-04-19 1991-04-19

Publications (1)

Publication Number Publication Date
NO933742L true NO933742L (en) 1993-10-18

Family

ID=24764088

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933742A NO933742L (en) 1991-04-19 1993-10-18 Human, bone derived, insulin-like growth factor binding protein

Country Status (11)

Country Link
EP (1) EP0580752A4 (en)
JP (1) JP2527896B2 (en)
KR (1) KR0129864B1 (en)
AU (1) AU658187B2 (en)
CA (1) CA2107475A1 (en)
CZ (1) CZ283601B6 (en)
FI (1) FI934588A0 (en)
HU (1) HUT70297A (en)
NO (1) NO933742L (en)
RU (1) RU2114120C1 (en)
WO (1) WO1992018154A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233155T2 (en) 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
CA2195474A1 (en) * 1994-07-20 1996-02-01 Cedo Martin Bagi Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
PT871730E (en) 1995-10-11 2004-11-30 Chiron Corp COMBINATION OF PDGF, KGF, IGF AND IGFBP FOR WOUND HEALING
SV2007000775A (en) 2001-01-05 2007-03-15 Pfizer ANTIBODIES AGAINST THE RECEIVER OF THE SIMILAR TO INSULIN GROWTH FACTOR
CN101014365B (en) * 2004-07-16 2011-04-13 辉瑞产品公司 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
EP3397644A4 (en) * 2015-12-31 2018-12-19 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
US10212614B2 (en) * 2015-12-31 2019-02-19 Facebook, Inc. Igniting network nodes in a multi-hop wireless network

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7907958A (en) * 1979-10-30 1981-06-01 Wijn Adriaan Jacques De CART OR FRAME FITTED WITH FOLDING WHEELS.
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
ES2063033T3 (en) * 1987-04-28 1995-01-01 Boehringer Mannheim Gmbh USE OF IGF-II IN THE TREATMENT OF BONE DISEASES.

Also Published As

Publication number Publication date
RU2114120C1 (en) 1998-06-27
EP0580752A1 (en) 1994-02-02
EP0580752A4 (en) 1994-08-24
FI934588L (en) 1993-10-18
CZ283601B6 (en) 1998-05-13
CA2107475A1 (en) 1992-10-20
JPH06501270A (en) 1994-02-10
KR0129864B1 (en) 1998-04-09
HU9302942D0 (en) 1994-01-28
WO1992018154A1 (en) 1992-10-29
FI934588A7 (en) 1993-10-18
HUT70297A (en) 1995-09-28
AU658187B2 (en) 1995-04-06
FI934588A0 (en) 1993-10-18
JP2527896B2 (en) 1996-08-28
CZ219093A3 (en) 1994-12-15
AU1784492A (en) 1992-11-17

Similar Documents

Publication Publication Date Title
DK0670729T3 (en) Use of insulin-like growth factors and analogues for the treatment of retinal nerve diseases
UA42747C2 (en) PEPTIDE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD FOR STIMULATING GROWTH HORMONE SECRETION
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
DE69231486D1 (en) COMPOSITION CONTAINING PDGF AND DEXAMETHASONE TO PROMOTE TISSUE REPAIR AND REGENERATION
AU6184890A (en) Device for irradiating laser beams
ES2043890T3 (en) NEW MEDICAL USE.
DE3851776D1 (en) Use of IGF-II for the treatment of bone diseases.
DK1059934T3 (en) Matrix protein preparations for wound healing
EE9700225A (en) A method of treating diabetes mellitus using KKF
AU3140589A (en) Composition inducing a binding
FI940375A0 (en) Peptides having organ protective effect, method for their preparation and their use in therapy
AU6682598A (en) Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
NO933742L (en) Human, bone derived, insulin-like growth factor binding protein
GR3000944T3 (en) Pharmaceutical composition containing thymus extract fractions
ES2187648T3 (en) METHOD FOR THE ADMINISTRATION OF PHARMACOS FOR GENE THERAPY.
EP0339905A3 (en) Wound healing compositions containing growth factors and retinoids
HU9300467D0 (en) Mixture of medical effect containing glutatione and antocithane derivatives
NZ503372A (en) Chemical supplementation of bone by exposing bone to a therapeutic compound and applying a potential difference across the bone or tissue
RU93058185A (en) GROWTH FACTOR, COMPOSITION, METHOD FOR MODULING ACTION OF THE FACTOR, METHOD OF TREATMENT, METHOD OF DELIVERY OF THE COMPOUND, METHODS OF ANALYSIS
AU2534595A (en) Angiotensin ii for improving fertilization
EP0588477A3 (en) Medicinal composition comprising tcf-ii
DE3770766D1 (en) ACTIVE SUBSTANCES FOR TUMOR TREATMENT.
ATE306278T1 (en) TREATING BONE DISEASES WITH ADRENOMEDULLIN
AU8543098A (en) Use of a retinoid type compound to modulate (in vivo) the decoupling activity ofthe protein ucp2
DE3485282D1 (en) COMPOSITION FOR TREATING BOUGIC TUMORS, ESPECIALLY IN ANIMALS.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application